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Abstract
Background: Infection with the protozoan Toxoplasma gondii causes serious public health problems and is of
great economic importance worldwide. Protection from acute toxoplasmosis is known to be mediated by CD8+ T
cells, but the T. gondii antigens and host genes required for eliciting protective immunity have been poorly
defined. The T. gondii dense granule protein 6 (GRA6), recently proved to be highly immunogenic and produces
fully immune protection in T. gondii infected BALB/c mice with an H-2L
d gene. The CD8+ T cell response of H-2L
d
mice infected by the T. gondii strain seemed to target entirely to a single GRA6 peptide HF10-H-2L
d complex.
Results: To determine whether a GRA6-based DNA vaccine can elicit protective immune responses to T. gondii in
BALB/c mice, we constructed a eukaryotic expression vector pcDNA3.1-HisGRA6 and tested its immunogenicity in a
mouse model. BALB/c mice were vaccinated intramuscularly with three doses of GRA6 DNA and then challenged
with a lethal dose of T. gondii RH strain tachyzoites. All immunized mice developed high levels of serum anti-GRA6
IgG antibodies, and in vitro splenocyte proliferation was strongly enhanced in mice adjuvanted with levamisole
(LMS). Immunization with pcDNA3.1-HisGRA6 with LMS resulted in 53.3% survival of challenged BALB/c mice as
compared to 40% survival of BALB/c without LMS. Additionally, immunized Kunming mice without an allele of H-
2L
d failed to survive.
Conclusions: Our result supports the concept that the acquired immune response is MHC restricted. This study
has a major implication for vaccine designs using a single antigen in a population with diverse MHC class I alleles.
Background
Infection with the intracellular parasite Toxoplasma gon-
dii is responsible for toxoplasmosis in humans and
other warm-blooded animals. In veterinary medicine, T.
gondii infection has economic importance due to abor-
tion and neonatal losses in domestic animals, or as a
source of transmission to humans [1-3]. Vaccination is
one of the most efficient strategies to prevent and con-
trol the spread of toxoplasmosis. A live attenuated vac-
cine has been developed for the prevention of chronic
infection in sheep [4]. However, it cannot be used in
humans because of the risk of reversion to a pathogenic
form [5].
The dense granule of T. gondii is a secretory vesicular
organelle, which produces proteins that participate in
the modification of the parasitophorous vacuole (PV)
and PV membrane for the maintenance of intracellular
parasitism in almost all nucleated host cells [6]. There
are 16 GRA proteins, GRA1-GRA10, GRA12, GRA14, 2
isoforms of nucleotide triphosphate hydrolase (NTPase I
and II) [7] and 2 protease inhibitors (TgPI 1 and 2)
[8,9]. All the GRA proteins are identified as excretory/
secretory antigens (ESP). Several of them are suitable as
DNA vaccines for immunity against toxoplasmosis.
Immunization of C3H mice with a plasmid expressing
granule protein 1 (GRA1) showed 75-100% protection
to challenge with T. gondii cysts [10]. DNA vaccination
with protein GRA1, GRA7, and rhoptry protein ROP2
induced protection against infection with different viru-
lent T. gondii strains in C3H mice but not in BALB/c
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taining the whole coding sequence, results in a 62% sur-
vival of susceptible C57BL/6 infected mice [12].
Intramuscular injection of sheep with a DNA liposome
formulated plasmid coding for GRA1, GRA4, GRA6 and
GRA7 is an effective system that induces a significant
immune response against T. gondii [13].
Protection from acute toxoplasmosis is mediated by
CD8+ T cells, but T. gondii antigens and host genes
required for eliciting protective immunity are poorly
defined [14]. The T. gondii dense granule protein 6
(GRA6), being highly immunogenic, is a candidate vac-
cine against toxoplasmosis. The HF10 peptide
(HPGSVNEFDF) is located at the carboxyl terminus of
GRA6 and is the immunodominant epitope to bind H-
2L
d major histocompatibility complex class I molecule
(MHC class I). It induces immune protection of BALB/c
mice carrying the H-2L
d molecule against T. gondii
infection. The CD8+ T cell response of BALB/c mice
infected by the T. gondii strain seemed to be targeted
entirely to the single GRA6 HF-H-2L
d complex [15].
Notably, similar focusing of the CD8+ T cell response
to a single antigen from the circumsporozoite protein of
Plasmodium yoelii and only a small subset of epitopes
of the trans-sialidase antigens of Trypanosoma cruzi has
been reported in mice [16,17]. DNA-based vaccination
is one of the most promising strategies for the develop-
ment of new generation effective vaccines against intra-
cellular parasites.
We have constructed the eukaryotic expression vector
named pcDNA3.1-HisGRA6 to determine whether DNA
immunization can elicit protective immune responses to
T. gondii. The present work shows that the partial pro-
tection against toxoplasmos i si nB A L B / cm i c ei n d u c e d
by DNA vaccination with T. gondii GRA6 gene. It has
implications for vaccine designs using a single antigen
in a population with diverse MHC class I alleles.
Materials and methods
Plasmid construction and preparation
The entire GRA6 open reading frame (ORF) was ampli-
fied by PCR from the cDNA of T. gondii (RH strain)
tachyzoites with primer RH-1 (5’-CGCGGATCCCGC-
CAGCATGGCACACGGTGGCATC-3’)a n dR H - 2( 5 ’-
GCATGCGGCCGCCTAATAATCAAACACATTCA-
CACG-3’). The PCR product was ligated into the pGEX-
4T-1 and pcDNA3.1 vectors (Invitrogen) at the BamH I
and Not I sites to construct two recombinant plasmids
pGEX-GRA6 and pcDNA3.1-HisGRA6. The two plas-
mids pGEX-GRA6 and pcDNA3.1-HisGRA6, carrying
t h eG R A 6g e n ew e r ep u r i f i e df r o mD H 5 a-competent
cells with an endotoxin-free DNA purification kit (Vig-
orous Biotechnology, Beijing). The integrity of these
inserts was verified by DNA sequencing and agarose gel
electrophoresis after digestion with appropriate restric-
tion enzymes. The control plasmid pcDNA3.1 was puri-
fied from the same E. coli strain using the same method
as purifying pcDNA3.1-HisGRA6. Plasmid pGEX-GRA6
was used for expressing the GRA6 protein in bacteria
and plasmid pcDNA3.1-HisGRA6 was used for immuni-
zation of mice and protein expression in mammalian
cells in vitro. DNA for immunization was dissolved in
sterile endotoxin-free PBS. The DNA concentration was
determined spectrometrically at 260 nm. The OD 260/
280 ratios for the purified DNA were 1.8-2.0, indicating
that there was no major protein contamination.
Mice and parasites
Six- to eight-week-old female BALB/c carrying H-2L
d
and Kunming (without H-2L
d) mice were purchased
from the Institute of Laboratory Animal Sciences, Chi-
nese Academy of Medical Sciences, Beijing. They were
maintained in groups of six per cage with food and
water provided ad libitum and artificial light for 12 h
per day. This study was conducted in compliance with
the regulations concerning the use of laboratory animals
of China Agricultural University. The RH strain of T.
gondii was maintained in our laboratory by passage of
tachyzoites in BALB/c mice or Vero cells. The T. gondii
tachyzoites used for challenge were cultured in Vero
cells in DMEM medium (Sigma, USA) supplemented
with 2% fetal calf serum, harvested by scrapping the
cells and purified by filtration on glass fiber [18].
Immunization
As shown in Figure 1, BALB/c mice received three
injections of 100 μg of pcDNA3.1-HisGRA6 DNA at 2-
week intervals in both tibialis anterior muscles. Kunm-
ing mice were immunized with pcDNA3.1-HisGRA6
and BALB/c with empty pcDNA3.1 as controls. One
group of BALB/c mice was immunized with pcDNA3.1-
HisGRA6 formulated in 1% LMS as the adjuvant. The
immunized mice were challenged intraperitoneally with
1, 000 tachyzoites of T. gondii RH strain (Type I). Sera
were collected at 0, 3, 5, 7 and 9 weeks post the first
immunization injection. Serum anti-GRA6 antibody
levels were detected by indirect ELISA. One week post
the last injection, the spleen was removed aseptically.
Splenic lymphocyte proliferation was tested using the
MTT assay. One week after the challenge, brain, liver
and spleen were removed and fixed in 10% formalin for
histological examination. Two weeks after the last
immunization, the animals were observed daily for
mortality.
Expression of GRA6 in Chinese hamster ovary (CHO) cells
The plasmid pcDNA3.1-HisGRA6 or the control plas-
mid pcDNA3.1 were transfected into CHO cells using a
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to the manufacturer’s instructions. CHO cells were cul-
tured in DMEM supplemented with FBS (10% v/v),
penicillin (200 U ml
-1) and streptomycin (20 mg ml
-1)i n
a humidified atmosphere of 5% CO2 at 37°C. The GRA6
mRNA transcription and protein expression in CHO
cells were confirmed by RT-PCR and western blotting,
respectively. The transfected CHO cells were processed
for identification of the GRA6 mRNA transcription by
RT-PCR and GRA6 protein expression by immunoblot-
ting according to the standard technique [19]. In brief,
cells were harvested 48 h after transfection, disrupted by
rapid freezing and thawing 3 times using liquid nitrogen,
the supernatant was obtained by centrifuging at 5, 000 g
for 15 min at 4°C. Proteins in the supernatant of the
samples were separated by SDS-PAGE and blotted onto
a PVDF membrane, which was then blocked with 5%
skimmed milk. The PVDF membrane was incubated for
1 h with murine anti-His antibodies (Tiangen, Beijing)
diluted 1:4000 in 5% skimmed milk, and incubated with
HRP-conjugated anti-mouse IgG (Southern Biotech,
USA) diluted 1:8000 in 5% skimmed milk. The conju-
gated substrate was detected using a chemiluminescent
dectection kit (CWBIO, China).
Expression of GST-GRA6 protein in bacteria
The plasmid pGEX-GRA6 was transformed to E. coli
BL21 (DE3) cells (Transgen Company, China) with
kanamycin selection. The recombinants were harvested
after 6 h of induction with IPTG (isopropyl b-D-1-Thio-
galactopyranoside). The glutathione-S-transferase
(GST)-GRA6 protein was purified using glutathione affi-
nity chromatography.
ELISA
Antigen-specific antibodies were quantified by enzyme-
linked immuno-sorbent assay (ELISA) as previously
described [20]. GST-GRA6 protein expressed in bacteria
was used as the coating antigen, and antigen-specific
antibodies were detected with HRP-labeled anti-mice
IgG. The assay was developed using TMB. The optical
density (OD) at 450 and 630 nm was measured by a
plate reader (Bio-Rad, CA, USA). The serum antibody
titer was defined as the highest dilution that gave a test/
naive serum OD ratio of 2.1 or higher.
Antigen-specific splenic lymphocyte proliferation
GRA6-stimulated splenic lymphocyte proliferation was
used to assess the cellular immune response of the
immunized mice. Three mice from each group were
killed 7 days after the last immunization and the spleen
was removed. Single cell suspensions were obtained by
filtration through a nylon mesh. Erythrocytes in the
spleen cell suspension were removed by lysis and the
remaining cells were washed and suspended in RPMI
1640 medium (GIBCO) supplemented with 5% FCS,
HEPES (10 mM), L-glutamine (2 mM), sodium pyruvate
(1 mM), b-mercaptoethanol (50 mM), gentamycin (50
mg/ml), penicillin (100 U/ml) and streptomycin (100
mg/ml). They were seeded in triplicate in flat-bottomed
96-well microtiter plates (Costar) at 5 × 10
5 cells per
well in 200 μl culture medium alone as the negative
control or with various concentrations of GST-GRA6
fusion protein, bovine serum albumin (BSA), or 5 μg/ml
concanavalin A as the positive control for 48-72 h at 37°
C. Then 20 μl MTT (5 mg/ml in PBS) was added to
each well. After 4 h of incubation at 41°C DMSO (100
μl/well) was added and the culture was further incu-
bated at 37°C for 10 min to arrest cell proliferation. The
optical density was measured by a plate reader at 490
nm. Data were expressed as stimulation index (SI),
which is the ratio of the mean OD value of triplicate
wells with antigen stimulation to the mean value of tri-
plicate wells of the negative control [21].
Histopathology
The formalin-fixed brain, liver and spleen tissues were
dehydrated with increasing concentrations of ethanol,
embedded in paraffin, sectioned and stained with hema-
toxylin and eosin for histological evaluation.
Statistical analysis
Levels of significance between groups of mice were
determined using the student’s t-test for mortality, anti-
body titers and T cell proliferation stimulation index.
Results
Construction of DNA vaccine
The GRA6 gene was cloned into the eukaryotic expres-
sion vector pcDNA3.1 using the restriction enzymes
BamH I and Not I. The transcription was driven by the
Figure 1 Experimental design.
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yotic expression vector also contains the CpG sequence
and the polyadenylation and 3’ splicing signals from
bovine growth hormone (Figure 2). The resulting vector
consisted of 698 bases of the entire sequence of the
ORF of the GRA6 gene, encoding 230 amino acids, fol-
lowed by a stop codon.
Expression of GRA6 in vitro
The expression of GRA6 in a prokaryotic system and a
eukaryotic system was investigated. In the prokaryotic
system, plasmid pGEX-GRA6, which has high protein
yield, was used for expressing GST-GRA6 fusion protein
in vitro. In the eukaryotic system, plasmid pcDNA3.1-
HisGRA6 was transfected into CHO cells. The level of
mRNA and protein expression was confirmed by RT-
PCR and Western blotting, respectively. Electrophoresis
of the RT-PCR product from RNA of CHO transfected
with pcDNA3.1-HisGRA6 showed one band of about
714 bp, corresponding to the positive plasmid control
(Figure 3A). RT-PCR product from RNA of CHO trans-
fected with the control pcDNA3.1(+) showed no similar
band.
The histidine tagged GRA6 protein of 32 kDa was
identified by Western blotting using anti-His monoclo-
nal antibodies (Figure 3B).
Humoral immune response induced by DNA vaccination
Vaccination with the plasmid DNA encoding GRA6
induced a strong antibody response. As shown in Figure
4, significant antibody responses were observed after the
second immunization in BALB/c mice. While BALB/c
mice were found to be good responders to the DNA
vaccine after the second immunization, Kunming mice
showed no immune response to the DNA vaccine (data
not shown). The IgG antibody titer was greater in the
sera of mice co-inoculated with LMS than in the sera of
mice immunized with pcDNA3.1-HisGRA6 alone, but
there was no statistically significant difference between
the two groups (P > 0.05).
Cellular immune response induced by DNA vaccination
To evaluate anti-GRA6 immune cellular responses in
the DNA-vaccinated mice, spleen cell suspensions were
prepared from each mouse one week post the last
immunization. Antigen specific proliferation of splenic
lymphocytes was determined using the MTT assay. Sig-
nificant GRA6-specific splenocyte proliferation was
observed for the BALB/c mice immunized with
pcDNA3.1-HisGRA6 alone or in combination with the
adjuvant, LMS. The proliferation was antigen-specific
since there was no expansion of splenocytes in the pre-
sence of a control protein BSA or from BALB/c mice
vaccinated with the control pcDNA3.1 vector in
response to GRA6 stimulation. Splenocytes from vacci-
nated Kunming mice did not proliferate when stimu-
lated with GRA6 protein (Figure 5).
Immunoprotection against lethal challenge
To determine whether the DNA vaccine could induce
immunoprotection against a lethal challenge of T. gon-
dii, BALB/c mice were immunized with pcDNA3.1-His-
GRA6 alone, or pcDNA3.1-HisGRA6 plus LMS and
challenged with T. gondii tachyzoites.
As shown in Figure 6, immunization of BALB/c mice
with pcDNA3.1-HisGRA6 significantly increased the
survival rate of these mice (40% survival) (P < 0.05) in
comparison with BALB/c immunized with the control
vector or Kunming mice immunized with pcDNA3.1-
HisGRA6 (0% survival) (P < 0.05). Survival was further
increased in mice immunized with pcDNA3.1-HisGRA6
plus LMS (53.3% survival cf. 40% without LMS; P <
0.05). Mice alive at week 12 stayed alive for at least 2
months.
Histopathological examination did not detect any
parasite in the brain, liver or spleen of BALB/c mice
immunized with pcDNA3.1-HisGRA6 alone or
pcDNA3.1-HisGRA6 plus LMS. Parasites were clearly
visible in the tissues of the control groups (Figure 7).
Discussion
In the present study, a DNA vaccine was constructed
based on the HF10 peptide sequence located at the car-
boxyl terminus of the GRA6 gene of T. gondii.T h e
results from pcDNA3.1-HisGRA6-transfected CHO cells
show that the recombinant GRA6 can be expressed in
eukaryotic cells in vitro. Our data demonstrated that a
Figure 2 Plasmid map of pcDNA(3.1)-GRA6.
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able to induce humoral and cellular immunity in mice
and confer partial protection against acute infection of
T. gondii. We also showed that immunogenicity of the
DNA vaccine was enhanced by a non-specific chemical
adjuvant, LMS. This is the first study demonstrating
that a single epitope based DNA vaccine induced pro-
tective immunity against the acute T. gondii infection.
The immune response to T. gondii infection is domi-
nated by CD8+ T cells, which is critical in the protec-
tion of hosts from intracellular parasite infection [22,23].
Resistance to toxoplasmic encephalitis has been linked
to the locus encoding H-2Ld MHC class I in mice car-
rying the H-2L
d gene [24]. Blanchard et al.[ 1 5 ]f o u n d
that the GRA6 protein, a polymorphic protein secreted
in the parasitophorous vacuole, is an immunodominant
antigen and elicited a protective CD8+ response in mice
through the presentation of a single decapeptide HF10
of GRA6 by the H-2L
d major histocompatibility complex
class I molecule. Based on the above findings, we
designed a DNA vaccine expressing the HF10 fragment
of GRA6, which was expected to induce strong cellular
immunity and confer good protective efficacy against
toxoplasmosis in BALB/c mice carrying the H-2L
d gene
but not in Kunming mice without the H-2L
d.I n d e e d ,
t w oi n j e c t i o n so ft h eD N Av a c c i n et oB A L B / cm i c e
induced strong GRA6-specific cellular and humoral
immunity as shown by a significant increase in serum
antibodies to GRA6 and splenic lymphocyte expansion
specific to GRA6 in vitro.
Immunization with the DNA vaccine conferred some
protection of mice from a lethal challenge with T. gondii
RH, but did not provide complete protection. Survival of
DNA-immunized mice ranged from 40 to 53%, com-
pared to 100% mortality of control mice immunized
with the empty vector or DNA-immunized Kunming
mice. The incomplete protection was possibly related to
the polymorphism of the carboxy-terminal region of
GRA6 in T. gondii strains [25]. HF10 (HPGSVNEFDF)
derived from the type II strain was not only an immu-
nodominant epitope, but was also able to elicit a protec-
tive CD8+ T cell response during the parasite infection
Figure 4 Anti-GRA6 antibody levels in BALB/c mice (n = 15) immunized with the pcDNA3.1-HisGRA6 plasmid on days 0, 14 and 28.
One group of BALB/c mice were immunized with the empty pcDNA3.1 as the control. Sera were collected at 0, 3, 5, 7 and 9 weeks post
immunization. Anti-GRA6 antibodies levels were determined by indirect ELISA. *p < 0.05
Figure 3 Identification of expression of GRA6 gene in CHO cells with RT-PCR and Western blot. A. Gel electrophoresis of RT-PCR products
from pGRA6-transfected or control plasmid pcDNA3.1-transfected CHO cells; B. Western blot of GRA6 protein expressed in CHO cells.
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gested by the failure of HF10-specific T cells to recog-
nize the corresponding GRA6 peptide from a type I
strain (HPERVNVFDY). Figure 8 showed the difference
of DNA and protein sequences of GRA6 from T. gondii
RH (type I) and T. gondii Pru (type II).
The use of adjuvants to improve vaccine efficacy is
w e l lk n o w n ,a n da d j u v a n ti su s e di nm a n yc o m m e r c i a l
vaccines for humans and animal species. The function
of adjuvants is believed to activate innate immunity, to
increase the interaction between antigen and antigen
presenting cells (APC) and to improve antigen proces-
sing or presentation in APC [26]. In this study, we used
a chemical adjuvant, LMS, which is quickly absorbed or
metabolized by tissues at the injection site. LMS has
been commonly used as an anthelmintic for domestic
animals for more than 30 years and also used in several
human clinical trials as an anticancer drug [27]. LMS
injected with a Foot-and-Mouth Disease Virus (FMDV)
DNA vaccine stimulated both humoral and cellular
immune responses in conjunction with strong produc-
tion of interferon (IFN)-g [28]. We also observed some
enhancement in our study, which may relate to LMS
affecting several important genes within the toll-like
pathway [29]. LMS might be an agonist that could acti-
vate innate response via TLR7/8 pathways. Indeed, CpG
motifs [30,31], derived from the eukaryotic vector, acti-
vated innate responses via the TLR9 pathway.
Figure 5 GRA6-specific proliferation response of splenocytes from BALB/c and Kunming mice immunized with the GRA6 DNA vaccine
and empty vector pcDNA3.1 vector. The mice (n = 15/group) were immunized on days 0, 14 and 28 with 100 μg pcDNA3.1-HisGRA6. Two
groups of mice, one group of Kunming mice were immunized with pcDNA3.1-HisGRA6 and one group of BALB/c mice immunized with empty
pcDNA3.1 were included as controls. The level of proliferation of splenocyte T cells in spleen was tested using the MTT method assay. *p < 0.05
Figure 6 Survival of BALB/c mice against a lethal challenge of T. gondii.B A L B / cm i c e( n = 15/group) were immunized on days 0, 14 and
28 with 100 μg pcDNA3.1-HisGRA6 or empty pcDNA3.1 and Kunming mice with pcDNA3.1-HisGRA6. The mice were challenged with 1, 000 T.
gondii RH strain tachyzoites 2 weeks after the last immunization, and observed daily for mortality.
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The DNA vaccine based on GRA6 of T. gondii can
induce strong humoral and cellular immunity and pro-
vide partial protection against toxoplasmosis in BALB/c
mice with an H-2L
d allele. Our result supports the
notion that the immune response to T. gondii is MHC
restricted. This study has major implications for vaccine
d e s i g n su s i n gas i n g l ea n t i g e ni nap o p u l a t i o nw i t h
diverse MHC class I alleles [32]. It provides a theoretical
basis for the vaccine design using a single immunodomi-
nant antigen for other pathogens for which T cells are
required for host protection.
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